Pages that link to "Q7088466"
Jump to navigation
Jump to search
The following pages link to olodaterol (Q7088466):
Displayed 35 items.
- Adrenoceptor beta 2 (Q287961) (← links)
- Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies (Q33783760) (← links)
- Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies (Q33890178) (← links)
- Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol (Q34011640) (← links)
- Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy (Q34094351) (← links)
- Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models (Q34108750) (← links)
- The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies (Q34123296) (← links)
- 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD. (Q34207787) (← links)
- Olodaterol: first global approval (Q38155451) (← links)
- Current and novel bronchodilators in respiratory disease (Q38163757) (← links)
- Tiotropium sustains the anti-inflammatory action of olodaterol via the cyclic AMP pathway (Q43630722) (← links)
- Striverdi (Q47522156) (← links)
- olodaterol / tiotropium (Q48566680) (← links)
- Bronchoprotection by olodaterol is synergistically enhanced by tiotropium in a guinea pig model of allergic asthma. (Q54488546) (← links)
- Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies. (Q55133367) (← links)
- Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD. (Q61920878) (← links)
- Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients (Q61975412) (← links)
- Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1) (Q61975849) (← links)
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (Q62062212) (← links)
- Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease (Q63317173) (← links)
- Japan Long-term Safety for Tiotropium Plus Olodaterol (Q63320408) (← links)
- Olodaterol Bridging Study in Asthma (Q63320542) (← links)
- A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma (Q63339119) (← links)
- Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPD (Q63401737) (← links)
- The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination (Q63573004) (← links)
- Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease (Q63574683) (← links)
- Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD (Q63597758) (← links)
- Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results (Q64228000) (← links)
- (Q86010928) (redirect page) (← links)
- Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® (2012-09-30) (Q86168395) (← links)
- Early Intervention Efficacy in COPD (Q86294770) (← links)
- Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece (Q113896642) (← links)
- A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD) (Q113922030) (← links)
- User:DeltaBot/fixClaims/maintenance/P715format (← links | edit)
- Wikidata:Database reports/Constraint violations/P2275 (← links | edit)